Phase I Study to Evaluate the Safety and Effectiveness of Dual CD33-CLL1 CAR-T Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Cyclophosphamide (Primary) ; Dual CD33/CLL1 targeting CAR-T therapy-Sichuan Kelun-Biotech Biopharmaceutical (Primary) ; Fludarabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 30 Aug 2021 New trial record